Montelukast API: A Comprehensive Insight for Healthcare Professionals, Researchers, and Users
Navigating the Montelukast API Market
Welcome to the world of Montelukast API, an important substance that has an effect on researchers, medical experts, and people who depend on its therapeutic effects. Join us as we explore the Montelukast API's key components and ramifications.
Growth at a Glance: Montelukast API Market Growth Rate
The Montelukast API Market is expanding at a rate that clearly demonstrates its importance in contemporary medicine. This market is expanding at a rate that is reflective of how well-known Montelukast is becoming. The increase rate demonstrates how this API is increasingly in demand to treat respiratory disorders.
The market size for montelukast API was estimated at USD 0.8 billion in 2022. During the projection period (2023-2032), the montelukast API market industry is anticipated to increase from USD 0.9 billion in 2023 to USD 2.30 billion, registering a compound yearly growth rate (CAGR) of 12.50%.
Leading the Way: Application Dominating Montelukast API Market
With 46.9% of market revenue (or $0.4 billion) coming from the asthma category, the market was dominated by this sector. Montelukast sodium is an asthma medication used to treat adults and children 12 months of age and older. It works by reducing symptoms like coughing, wheezing, breathing problems, and chest tightness.
The Mystery of Singulair's Market Exit
Singulair (montelukast) was not taken off the market. However, the FDA strengthened its earlier warning concerning the possibility of neuropsychiatric problems by adding a boxed warning to Singulair in 2020. After reviewing several reports of significant mental health side effects, including suicidal thoughts and deeds, among Singulair-using patients, the FDA issued this warning.
Manufacturers Behind Montelukast API
Montelukast API is produced in India by Dr. Reddy's Laboratories. Leading Indian pharmaceutical business Dr. Reddy's has operations all over the world. One of the biggest suppliers of montelukast API globally, the company has been producing it for more than ten years.
A division of Merck & Co., Inc., Merck Sharp & Dohme Corp. produces montelukast API in the US. An international pharmaceutical business called Merck Sharp & Dohme has been producing montelukast API for more than 20 years. In Wilson, North Carolina, the business operates a cutting-edge production facility that is outfitted with the most recent technologies. Montelukast API from Merck Sharp & Dohme is additionally examined for quality and purity by outside labs.
A Glimpse into 2024: Montelukast API Recalls
Yes, there is a recall for some lots of montelukast sodium oral granules in the United States in 2024. Teva Pharmaceuticals USA, Inc. issued the recall on April 6, 2023, as a result of the discovery of an impurity that was beyond the allowable limit. Nationwide throughout the United States and Canada, the recalled lots were sold.
N-nitrosodimethylamine (NDMA), a possible human carcinogen, is the impure substance in concern. It is unknown whether the active ingredient in montelukast sodium contains NDMA, which can develop during the production process of some pharmaceuticals.
The following lots of oral granules of montelukast sodium are subject to the recall:
· Lot number: 3007556A
· Expiration date: 03/2024
· NDC number: 0093-7487-56
What is the new warning on montelukast?
A prescription drug used to treat asthma and allergies called montelukast (Singulair) received a stronger warning from the US Food and Drug Administration (FDA) in March 2020. The new warning notes that even in patients who have no prior history of mental health issues, montelukast can have substantial mental health side effects, including suicidal thoughts and behaviours.
In closing, the world of Montelukast API is extremely important to both medical professionals and those who use it therapeutically. Montelukast API highlights its significance in contemporary healthcare by the supremacy of its use, market expansion, and function in treating respiratory problems. While the discontinuation of Singulair may have made a change, Montelukast API still offers effective treatments for respiratory health issues. Let's keep in mind that education is the key to making wise decisions about our health and wellbeing as we traverse the pharmaceutical landscape.
